EBITDA: Income before interest, taxes, depreciation and amortization.
Swedish Orphan Biovitrum (BIOVF) had EBITDA of $387.17M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$817.26M |
|
$-304.16M |
|
$169.63M |
|
$647.63M |
|
$1.22B |
|
$-405.58M |
|
$-17.66M |
|
$-423.24M |
|
$-423.24M |
|
$-304.26M |
|
$-304.26M |
|
$-304.16M |
|
$-304.26M |
|
$-405.58M |
|
|
EBITDA |
$387.17M |
344.65M |
|
347.87M |
|
$-0.88 |
|
$-0.87 |
|
| Balance Sheet Financials | |
$1.50B |
|
$172.26M |
|
$5.54B |
|
$7.04B |
|
$1.47B |
|
$922.36M |
|
$1.79B |
|
$3.26B |
|
$3.78B |
|
$-1.44B |
|
$3.78B |
|
344.66M |
|
| Cash Flow Statement Financials | |
$586.88M |
|
$-338.11M |
|
$-254.76M |
|
$119.81M |
|
$109.20M |
|
$-10.62M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.02 |
|
-- |
|
-- |
|
0.20 |
|
0.37 |
|
79.24% |
|
-49.63% |
|
-49.63% |
|
-- |
|
-51.79% |
|
-37.22% |
|
$583.20M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.35 |
|
0.91 |
|
99.05 |
|
-8.05% |
|
21.07% |
|
-4.32% |
|
-6.47% |
|
$10.97 |
|
$1.68 |
|
$1.69 |
|